Demand for $84,000 Hepatitis C Drug Slows
Demand for $84,000 Hepatitis C Drug Slows – After recording the best launch of any drug in history, it looks like the pace is starting to slow down for Gilead Sciences’ Sovaldi, the new $84,000 hepatitis C cure that’s sparking a new focus on specialty drug costs.
Data released by CVS Health on Tuesday show that use of Sovaldi has slowed down since May after the drug’s record-setting start last December. The slowdown can partly be explained by the health-care industry’s anticipation of more hepatitis C treatments soon hitting the market, including another one from Gilead that could gain FDA approval any day now.
Category: News
